Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT03437941 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
39
Enrollment
INDUSTRY
Sponsor class

Stopped The level of benefit observed did not justify enrolling patients in the Dose Expansion phase of the study.

Conditions

Interventions

Sponsor

Corcept Therapeutics